Patents by Inventor Nora M. Chapman

Nora M. Chapman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Live attenuated viruses for use as vectors or vaccines
    Patent number: 7189401
    Abstract: The present invention provides modified viral genomes for use as vaccines or vectors, which are improved in their ability to retain attenuating mutations. The genomes are from viruses that replicate by way of an RNA-dependent RNA or DNA polymerase. The genomes are modified in the pol gene to encode polymerases that catalyze slower replication, have increased transcriptional fidelity, or are otherwise altered such that the reversion rate of the modified virus to a non-attenuated form is decreased as compared to an equivalent, unmodified virus. In particular, modified coxsackievirus genomes are disclosed.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: March 13, 2007
    Assignee: University of Nebraska Board of Regents
    Inventors: Steven M. Tracy, Nora M. Chapman
  • Coxsackievirus vectors and their use in prevention and treatment of disease
    Publication number: 20030190329
    Abstract: The present invention is drawn to the use of attenuated coxsackievirus cardiotropic virus vectors as efficient gene transfer vectors to deliver immunomodulatory or other biologically active proteins and/or antigenic epitopes in transient infections to aid in preventing, ameliorating, and/or ablating infectious viral heart disease and reducing, or ablating entirely, heart transplant rejection. Specifically disclosed are univalent and multivalent vaccines for certain viruses, including adenovirus and coxsackieviruses. Also disclosed are compositions and methods for suppressing onset of type 1 diabetes, using vectors of the invention that express immunomodulatory proteins, specifically IL-4.
    Type: Application
    Filed: March 26, 2001
    Publication date: October 9, 2003
    Inventors: Steven M. Tracy, Nora M. Chapman
  • Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
    Patent number: 6323024
    Abstract: The present invention is drawn to the use of attenuated Coxsackievirus cardiotropic virus vectors as efficient gene transfer vectors to deliver immunomodulatory or other biologically active proteins and/or antigenic epitopes in transient infections to aid in preventing, ameliorating, and/or ablating infectious viral heart disease and reducing, or ablating entirely, heart transplant rejection. Additionally, other organs or tissues may be targeted with specific picornaviruses. In particular, an attenuated CVB3 viral vector able to express a cytokine is provided. This cytokine-expressing viral vector is able to deliver the cytokine to a target tissue and reduce disease symptoms.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: November 27, 2001
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Steven M. Tracy, Nora M. Chapman, Peter Kolbeck, James M. Malone, III
  • Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
    Patent number: 6071742
    Abstract: The present invention is drawn to the use of artificially attenuated Coxsackievirus B3 cardiotropic virus vectors as efficient gene transfer vectors to deliver immunomodulatory proteins and/or antigenic epitopes in transient infections to aid in preventing, ameliorating, and/or ablating infectious viral heart disease and reducing, or ablating entirely, heart transplant rejection. Additionally, other organs or tissues may be targeted with specific picornaviruses. An attenuated CVB3 viral vector able to express a cytokine is provided.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: June 6, 2000
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Steven M. Tracy, Nora M. Chapman, Peter Kolbeck, James Malone